Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622889 | 0.77 | AAK1 (0.34) | AAK1FERMT2XIAPBIRC2 | |
| SCHEMBL22972418 | 0.77 | AAK1 (0.34) | AAK1FERMT2XIAPBIRC2 | |
| SCHEMBL16110837 | 0.77 | AAK1 (0.34) | AAK1FERMT2XIAPBIRC2 | |
| SCHEMBL29622975 | 0.77 | AAK1 (0.40) | AAK1FERMT2XIAPBIRC2 | |
| SCHEMBL4758327 | 0.77 | AAK1 (0.40) | AAK1FERMT2XIAPBIRC2 | |
| SCHEMBL16132325 | 0.77 | AAK1 (0.41) | AAK1FERMT2PIK3R2XIAPBIRC2 | |
| SCHEMBL4619983 | 0.74 | PARP1 (0.44) | PIK3R2 | |
| SCHEMBL4619603 | 0.71 | FERMT2 (0.49) | AAK1SMN1; SMN2FERMT2CCR1CCR5 | |
| SCHEMBL14446374 | 0.71 | ALDH1A1 (0.37) | AAK1SMN1; SMN2CCR1CCR5CCR8 | |
| SCHEMBL13633973 | 0.71 | MKNK1 (0.35) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | AAK1 1161/4885SMN1; SMN2 3186/4885FERMT2 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.